Moderna (MRNA)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$1.56 (+3.63%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Moderna (MRNA)
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Key Insights

Critical company metrics and information
  • Share Price

    $44.44
  • Market Cap

    $17.10 Billion
  • Total Outstanding Shares

    384.82 Million Shares
  • Total Employees

    5,600
  • Dividend

    No dividend
  • IPO Date

    December 7, 2018
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Homepage

    https://www.modernatx.com

Historical Stock Splits

If you bought 1 share of MRNA before July 22, 2010, you'd have 0.00 shares today.
Execution DateSplit Amount
August 3, 20171-for-10 (Reverse Split)
December 23, 20111-for-10 (Reverse Split)
July 22, 20101-for-4 (Reverse Split)

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow$-1.31 Billion
Net Cash Flow From Investing Activities$1.95 Billion
Net Cash Flow From Operating Activities, Continuing$-3.21 Billion
Net Cash Flow From Operating Activities$-3.21 Billion
Net Cash Flow From Financing Activities, Continuing$-50.00 Million
Net Cash Flow From Investing Activities, Continuing$1.95 Billion
Net Cash Flow, Continuing$-1.31 Billion
Net Cash Flow From Financing Activities$-50.00 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Diluted Earnings Per Share$5.82
Operating Expenses$6.12 Billion
Diluted Average Shares$782.00 Million
Revenues$5.08 Billion
Income/Loss From Equity Method Investments$-62.00 Million
Preferred Stock Dividends And Other Adjustments$0.00
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Income/Loss From Continuing Operations After Tax$-2.22 Billion
Net Income/Loss$-2.22 Billion
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Other Operating Expenses$1.29 Billion
Net Income/Loss Attributable To Parent$-2.22 Billion
Benefits Costs and Expenses$7.43 Billion
Research and Development$4.83 Billion
Net Income/Loss Available To Common Stockholders, Basic$-2.22 Billion
Costs And Expenses$7.77 Billion
Income Tax Expense/Benefit$-129.00 Million
Income/Loss Before Equity Method Investments$-2.29 Billion
Cost Of Revenue$1.65 Billion
Gross Profit$3.43 Billion
Operating Income/Loss$-2.69 Billion
Basic Average Shares$768.00 Million
Income/Loss From Continuing Operations Before Tax$-2.35 Billion
Basic Earnings Per Share$5.82

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Equity Attributable To Parent$11.93 Billion
Equity$11.93 Billion
Inventory$412.00 Million
Equity Attributable To Noncontrolling Interest$0.00
Wages$244.00 Million
Other Current Liabilities$1.58 Billion
Assets$15.80 Billion
Accounts Payable$373.00 Million
Liabilities And Equity$15.80 Billion
Other Current Assets$9.25 Billion
Noncurrent Liabilities$1.68 Billion
Current Liabilities$2.20 Billion
Liabilities$3.88 Billion
Current Assets$9.67 Billion
Noncurrent Assets$6.14 Billion

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Related Companies

View additional S&P 500 companies similar to Moderna (MRNA)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.